Thursday, November 21, 2013
The use of platelet integrin a2bb3
inhibitors in thrombosis, while clinically very effective, is associated with a
high risk of bleeding that has limited their use. Now, researchers at the University of Illinois at
Chicago have applied their new insights into the
integrin-signaling mechanism to develop an integrin a2bb3 inhibitor that suppresses arterial thrombosis without
triggering bleeding in mice.1
Breaking the wave
Boettner, B. SciBX 6(45); doi:10.1038/scibx.2013.1280 Published online
Nov. 21, 2013
1. Shen, B. et al.
Nature; published online Oct. 27, 2013; doi:10.1038/nature12613 Contact:
Xiaoping Du, University of Illinois at Chicago, Ill. e-mail: firstname.lastname@example.org
2. Coller, B.S. J.
Clin. Invest. 122, 4293-4299 (2012)
Bayer AG (Xetra:BAYN),
Boehringer Ingelheim GmbH, Ingelheim, Germany
Eisai Co. Ltd. (Tokyo:4523),
Johnson & Johnson (NYSE:JNJ),
New Brunswick, N.J.
Lerner Research Institute at the
Cleveland Clinic, Cleveland, Ohio
The Medicines Co. (NASDAQ:MDCO),
Merck & Co. Inc. (NYSE:MRK),
Whitehouse Station, N.J.
Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan
(Euronext:SAN; NYSE:SNY), Paris, France
University of Illinois at Chicago, Chicago, Ill.